Wednesday, October 14, 2026
ExploreSearch
Finance Via News
Via News Knowledge File

Johnson & Johnson Services, Inc.

organization80% conf.·synced Oct 14, 2026

Uses biomarkers to advance drug development and personalized treatment approaches across oncology, immunology, and neuroscience

60
sourced metrics
1265
relationships
20
stated objectives
0
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Price 52 Week High
278.43USD
Oct 13, 2026reference only
Market Cap
599124890200USD
Oct 13, 2026reference only
Price 52 Week Low
186.00USD
Oct 13, 2026reference only
Stock Return Ytd
19.9%
Oct 13, 2026reference only
Stock Price
248.61USD
Oct 13, 2026reference only
Shares Outstanding
2409898597.0shares
Jul 17, 2026reference only
Revenue
25310000000.0USD
Jun 28, 2026reference only
Stockholders Equity
84971000000.0USD
Jun 28, 2026reference only
Cost Of Revenue
8051000000.0USD
Jun 28, 2026reference only
Total Assets
201061000000.0USD
Jun 28, 2026reference only
Gross Profit
17259000000.0USD
Jun 28, 2026reference only
Total Liabilities
116090000000.0USD
Jun 28, 2026reference only
Cash
20422000000.0USD
Jun 28, 2026reference only
Eps
2.27USD_per_share
Jun 28, 2026reference only
Net Income
5534000000.0USD
Jun 28, 2026reference only
Operating Cash Flow
2514000000.0USD
Mar 29, 2026reference only
Capex
1049000000.0USD
Mar 29, 2026reference only
Rd Expense
109000000.0USD
Dec 28, 2025reference only

Stated objectives

Achieve full-year 2025 sales of $93.5B-$93.9B, representing growth of 5.4%-5.9%

source
target: 93.5-93.9 billion USD stated

Improve adjusted pretax operating margin by approximately 300 basis points driven by cost savings and reduced acquired IPR&D costs

source
target: ~300 bps improvement stated

Achieve 2026 top-line growth of more than 5%, exceeding consensus of ~4.6%

source
target: >5% revenue growth stated

Achieve 2026 adjusted EPS approximately $0.05 above consensus of $11.39, implying ~$11.44

source
target: ~$11.44 adjusted EPS stated

Submit OTTAVA robotic surgical system for regulatory approval in the United States

source
target: Regulatory submission completed stated

Achieve higher operational sales growth in both Innovative Medicine and MedTech segments in 2026

source
by 2026-01-01 00:00:00stated

Improve MedTech growth and margins by completing the pending separation of the Orthopaedics franchise

source
stated

Strengthen presence in the neurological and psychiatric drug market via acquisition of Intra-Cellular Therapies

source
stated

Develop and deploy Ottava next-generation robotic surgery platform with AI-enabled ecosystem

source
stated

J&J expects sales growth in both Innovative Medicine and MedTech segments to be higher in 2026

source
target: higher than 2025 growth rates by 2026-01-01 00:00:00stated

Relationship graph · 1265 connections

Developed by
515
Competes with
133
subsidiary of
81
Covered by
73
Employs
67
Owns
59
acquired by
52
regulates
36
board member of
Joaquin Duato
This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com